摘要
我们评价了用于预测主观认知损伤(SCI)、遗忘或非遗忘轻度认知障碍(aMCI患者,naMCI)进展为阿尔茨海默氏病(AD)患者的疾病状态指数(DSI)方法的性能。DSI模型根据有效的数据测量类似于诊断病例的病人,如认知测试中,APOE基因型、CSF生物标志物和MRI确诊病例。我们从DESCRIPA队列,其中非痴呆的患者(N =775)与认知功能障碍不同亚型随访1至5年开展的DSI模型数据。采用留一交叉验证对亚组分类精度的DSI进行计算。在预测发展为AD的DSI的分类准确度为0.75(AUC=0.83),在总人口中,0.70(AUC=0.77)的aMCI患者和0.71(AUC=0.76)的naMCI。大约一半的患者具有高或低的DSI值的子集,精度达到0.86(全部),0.78(aMCI患者)和0.85(naMCI)。患者的MRI或CSF生物标志物的数据是可用,得到0.78(全部),0.76(aMCI患者)和0.76(naMCI)的精确度;而对于明确的案例,精度上升到0.90(全部),0.83(aMCI患者)和0.91(naMCI)。结果表明,该DSI模型可以分辨清晰和模糊的案例,评估疾病的严重程度,并且还提供在不同的生物标志物的有效性。特定测试或生物标记物可能混淆对于个体患者的分析,联合几种不同类型的试验和生物标记物能够揭示疾病的轨迹和提高对AD发展情况的预测。
关键词: 阿尔茨海默氏病,脑脊髓液(CSF),计算机辅助诊断,痴呆,DESCRIPA,磁共振成像(MRI),轻度认知障碍(MCI)。
Current Alzheimer Research
Title:Predicting Progression from Cognitive Impairment to Alzheimer’s Disease with the Disease State Index
Volume: 12 Issue: 1
Author(s): Anette Hall, Jussi Mattila, Juha Koikkalainen, Jyrki Lotjonen, Robin Wolz, Philip Scheltens, Giovanni Frisoni, Magdalini Tsolaki, Flavio Nobili, Yvonne Freund-Levi, Lennart Minthon, Lutz Frolich, Harald Hampel, Pieter Jelle Visser and Hilkka Soininen
Affiliation:
关键词: 阿尔茨海默氏病,脑脊髓液(CSF),计算机辅助诊断,痴呆,DESCRIPA,磁共振成像(MRI),轻度认知障碍(MCI)。
摘要: We evaluated the performance of the Disease State Index (DSI) method when predicting progression to Alzheimer’s disease (AD) in patients with subjective cognitive impairment (SCI), amnestic or non-amnestic mild cognitive impairment (aMCI, naMCI). The DSI model measures patients’ similarity to diagnosed cases based on available data, such as cognitive tests, the APOE genotype, CSF biomarkers and MRI. We applied the DSI model to data from the DESCRIPA cohort, where non-demented patients (N=775) with different subtypes of cognitive impairment were followed for 1 to 5 years. Classification accuracies for the subgroups were calculated with the DSI using leave-one-out crossvalidation. The DSI’s classification accuracy in predicting progression to AD was 0.75 (AUC=0.83) in the total population, 0.70 (AUC=0.77) for aMCI and 0.71 (AUC=0.76) for naMCI. For a subset of approximately half of the patients with high or low DSI values, accuracy reached 0.86 (all), 0.78 (aMCI), and 0.85 (naMCI). For patients with MRI or CSF biomarker data available, theywere 0.78 (all), 0.76 (aMCI) and 0.76 (naMCI), while for clear cases the accuracies rose to 0.90 (all), 0.83 (aMCI) and 0.91 (naMCI). The results show that the DSI model can distinguish between clear and ambiguous cases, assess the severity of the disease and also provide information on the effectiveness of different biomarkers. While a specific test or biomarker may confound analysis for an individual patient, combining several different types of tests and biomarkers could be able to reveal the trajectory of the disease and improve the prediction of AD progression.
Export Options
About this article
Cite this article as:
Anette Hall , Jussi Mattila , Juha Koikkalainen , Jyrki Lotjonen , Robin Wolz , Philip Scheltens , Giovanni Frisoni , Magdalini Tsolaki , Flavio Nobili , Yvonne Freund-Levi , Lennart Minthon , Lutz Frolich , Harald Hampel , Pieter Jelle Visser and Hilkka Soininen , Predicting Progression from Cognitive Impairment to Alzheimer’s Disease with the Disease State Index, Current Alzheimer Research 2015; 12 (1) . https://dx.doi.org/10.2174/1567205012666141218123829
DOI https://dx.doi.org/10.2174/1567205012666141218123829 |
Print ISSN 1567-2050 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5828 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Commentary Research Highlights (Amyloid β-Peptide and Alzheimer’s Disease: It’s All the RAGE)
CNS & Neurological Disorders - Drug Targets Epidemiology and Costs of Hypertension-related Disorders
Current Pharmaceutical Design Energy Expenditure of Hunter-Gatherers: When Statistics Turns to be Unreliable
Endocrine, Metabolic & Immune Disorders - Drug Targets Intravenous Thrombolysis with rt-PA in Acute Stroke Patients Aged ≥80 Years
Letters in Drug Design & Discovery Longitudinal Neuropsychological Outcome in Taiwanese Alzheimer's Disease Patients Treated with Medication
Current Alzheimer Research Mental Training for Cognitive Improvement in Elderly People: What have We Learned from Clinical and Neurophysiologic Studies?
Current Alzheimer Research Meet Our Editorial Board Member
Current Alzheimer Research Editorial: In Silico Studies in Drug Research Against Neurodegenerative Diseases
Current Neuropharmacology A Synopsis on the Role of Tyrosine Hydroxylase in Parkinson’s Disease
CNS & Neurological Disorders - Drug Targets Neuroimaging Features of Acquired Metabolic and Toxic Encephalopathies
Current Medical Imaging Clinical and Forensic Signs Related to Cocaine Abuse
Current Drug Abuse Reviews Current Status of Hormone Replacement Therapy in Post Menopausal Women
Current Drug Therapy Clinical and Environmental Correlates of Serum BDNF: A Descriptive Study with Plausible Implications for AD Research
Current Alzheimer Research From Dual Binding Site Acetylcholinesterase Inhibitors to Multi-Target-Directed Ligands (MTDLs): A Step Forward in the Treatment of Alzheimers Disease
Mini-Reviews in Medicinal Chemistry Glucocorticoid Receptor Antagonists
Current Topics in Medicinal Chemistry <i>In-silico</i> Studies and Biological Activity of Potential BACE-1 Inhibitors
Combinatorial Chemistry & High Throughput Screening Biomarkers of Alzheimer's Disease Risk in Peripheral Tissues; Focus on Buccal Cells
Current Alzheimer Research Cardiovascular Toxicity of Cyclooxygenase Inhibitors and Promising Natur a l Substitutes
Current Pharmaceutical Design Cardiomyopathy of Pregnancy
Current Women`s Health Reviews A beta oligomerization A Therapeutic Target for Alzheimers Disease
Current Medicinal Chemistry - Immunology, Endocrine & Metabolic Agents